ARCHIVES

Anamorelin Increases Body Mass In Two Global Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Caplan Receives NSB Public Service Award

March 28, 2014

FDA Faces Severe Regulatory, Scientific Needs, Report Finds.

February 1, 2008

Advisors approve set-aside for alternative medicine “best case series.”

November 19, 2004

ASCO Seeks “Nothing Less Than A Smoke-Free World”

June 6, 2003

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

October 28, 2011

FDA Backs Down, Releases INDs, But Revives Controversy Over Clinical Testing Guidelines

March 12, 1976